A reliable predictor for early recovery of consciousness in comatose patients is of great clinical significance. Here we aimed to investigate the potentially prognostic value of electroencephalogram-reactivity (EEG-R) in combination with sleep spindles, termed EEG-awakening, for behavioral awakening in etiologically diverse comatose patients. We performed a prospectively observational study on a sample of patients, all of whom were in coma lasting longer than 3 days. Continuous EEG monitoring was performed for at least 24 h to detect the presence of EEG-R and sleep spindles. We then followed patients for 1 month to determine their subsequent level of consciousness, classifying them as either awakened or non-awakened. Finally, Univariate and multivariate analyses were employed to assess the association of predictors with consciousness recovery. One hundred and six patients with different etiologies leading to coma were included in the study. Of these, 48 patients (45.3 %) awoke and 58 patients (54.7 %) did not awake in the month after the onset of the study. Of note, 26 patients (24.5 %) had a good neurological outcome, and 31 patients (29.3 %) died. Univariate analysis revealed that the Glasgow Coma Scale (GCS) score, EEG-R, sleep spindles, and EEG-awakening were all associated with one-month awakening. Comparisons of the area under the receiving operator characteristic curve (AUC) showed that EEG-awakening (0.839; 0.757–0.921) was superior to all of the following: EEG-R (0.798; 0.710–0.886), sleep spindles (0.772; 0.680–0.864), and GCS scores (0.720; 0.623–0.818). However, age, gender, etiology, and pupillary light reflex did not correlate significantly with one-month awakening. Further logistic regression analysis showed that only EEG-awakening and GCS scores at study entry were significant independent predictors of awakening and that the prognostic model containing these two variables yielded an outstanding predictive performance with an AUC of 0.903. EEG-awakening incorporates both EEG-R and sleep spindles and is an excellent predictor for early behavioral awakening in comatose patients. The prognostic model combining EEG-awakening and GCS scores shows an outstanding discriminative power for awakening.
Objective: This study investigates the application of metagenomic next-generation sequencing (mNGS) in the diagnosis of neurobrucellosis (NB). Methods: We retrospectively analyzed patients diagnose... Plain language summary Neurobrucellosis (NB) is a disease of the nervous system caused by a type of bacteria called Brucella. It is rare, serious and manifests inconsistently, making it hard to dia... Tweetable abstract Neurobrucellosis (NB) is a rare and severe disease with atypical manifestations, which makes diagnosis very difficult. This article showed that CSF metagenomic next-generation se...
Reactive astrogliosis and acidosis, common features of epileptogenic lesions, express a high level of astrocytic acid-sensing ion channel-1a (ASIC1a), a proton-gated cation channel and key mediator of responses to neuronal injury. This study investigates the role of astrocytic ASIC1a in cognitive impairment following epilepsy. Status epilepticus (SE) in C57/BL6 mice was induced using lithium–pilocarpine; the impact of ASIC1a on astrocytes was assessed using rAAV–ASIC1a–NC and rAAV–ASIC1a–shRNA, injected in the CA3 region of mice. Behavioral assessments were conducted using the Morris water maze (MWM). Western blotting and immunofluorescence were applied to evaluate ASIC1a and Gfap expression while analyzing intracellular calcium and extracellular glutamate (Glu) concentrations in primary cultured astrocytes isolated from the brains of 1 to 3-day-old mice and treated LPS. Results showed enhanced astrocyte proliferation and ASIC1a expression in the dentate gyrus of epileptic mice 7, 21, and 28 days post-SE (all p < 0.05). Escape latency in the MWM further suggested that ASIC1a regulates cognitive function in mice with chronic epilepsy. LPS stimulation in vitro mimicked inflammatory responses, increasing ASIC1a after 24 h, which increased the concentration of intracellular calcium and extracellular expression of Glu; inhibition of ASIC1a expression reversed this process. To sum up, these data confirm that astrocytic ASIC1a may facilitate cognitive dysfunction post-epilepsy, presenting a potential therapeutic target.
The management of severe neurologic infections due to multidrug-resistant (MDR) Klebsiella pneumoniae infection remains a challenge. Limited antibiotic treatment regimens make treatment of severe M...
23 June 2026 in Frontiers in Cellular and Infection Microbiology
Background: Distinguishing between bacterial meningitis (BM) and tuberculous meningitis (TBM) is a persistent clinical dilemma, further complicated by widespread empirical antibiotic use. This study evaluated the diagnostic and prognostic utility of cerebrospinal fluid procalcitonin (CSF-PCT) and other laboratory markers, analyzing all enrolled patients irrespective of prior antibiotic exposure. Methods: A prospective cohort analysis was conducted from September 2014 to September 2025, consecutively enrolling 125 BM patients and 56 TBM patients. Patients were included regardless of their pre - admission antibiotic treatment history. Demographic and laboratory parameters upon admission were analyzed. Receiver operating characteristic and multivariate logistic regression analyses were employed to identify biomarkers for differentiating BM from TBM and predictors of unfavorable outcomes (Glasgow Coma Scale score ≤8 at discharge) in BM. Results: The majority (89.5%) of patients had prior antibiotics. CSF-PCT and CSF neutrophil percentage demonstrated comparable efficacy in distinguishing BM from TBM, with area under the curve (AUC) values of 0.772 and 0.786, respectively. A combined model integrating both biomarkers achieved superior diagnostic performance (AUC = 0.849), significantly outperforming either marker alone (both P < 0.01). Multiple logistic regression analysis identified CSF-PCT >0.08 ng/mL (OR = 3.816), CSF neutrophil percentage >39% (OR = 20.253), and serum interleukin-6 (IL-6) >17.65 pg/mL (OR = 6.507) as independent discriminators of BM from TBM. Additionally, elevated CSF-PCT (>0.271 ng/mL) was the sole independent predictor for short-term adverse outcomes in BM (adjusted OR = 7.111, AUC = 0.727). Conclusion: The combination of CSF-PCT and CSF neutrophil percentage serves as a reliable biomarker for differentiating BM from TBM. CSF-PCT stands as an independent risk factor for unfavorable short-term outcomes in BM. These findings confirm the clinical utility of these biomarkers in early diagnosis and risk stratification, which remains effective in the routine clinical setting where patients commonly present with a history of antibiotic use.